China Reform Health Management and Services Group Co., Ltd. (SHE:000503)
10.29
-0.08 (-0.77%)
Jun 6, 2025, 2:45 PM CST
SHE:000503 Revenue
China Reform Health Management and Services Group had revenue of 50.47M CNY in the quarter ending March 31, 2025, with 5.33% growth. This brings the company's revenue in the last twelve months to 359.45M, up 11.53% year-over-year. In the year 2024, China Reform Health Management and Services Group had annual revenue of 356.90M with 8.11% growth.
Revenue (ttm)
359.45M
Revenue Growth
+11.53%
P/S Ratio
28.15
Revenue / Employee
281.04K
Employees
1,279
Market Cap
10.12B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 356.90M | 26.77M | 8.11% |
Dec 31, 2023 | 330.13M | 19.05M | 6.12% |
Jan 1, 2023 | 311.08M | 58.56M | 23.19% |
Jan 1, 2022 | 252.52M | 45.14M | 21.77% |
Dec 31, 2020 | 207.37M | 77.46M | 59.62% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Jiangsu Hengrui Medicine | 29.19B |
Shenzhen Mindray Bio-Medical Electronics | 35.59B |
WuXi AppTec | 39.59B |
Zhangzhou Pientzehuang Pharmaceutical., | 10.76B |
Sichuan Biokin Pharmaceutical | 5.82B |
Aier Eye Hospital Group | 21.81B |
Shanghai United Imaging Healthcare | 10.43B |
Yunnan Baiyao Group Co.,Ltd | 40.10B |